A 17% Reduction in Overall Cancer Risk A landmark study published in JAMA Oncology (Dai H et al., August 2025), drawing on data from 14 health systems encompassing approximately 20 million patients, found that adults with obesity who were prescribed GLP-1 receptor agonists had a 17% lower risk of developing cancer compared to carefully matched non-users
Understanding HRT and GLP-1 medications Before exploring how these therapies work together, it helps to understand what each one does independently
They mimic the naturally occurring hormone GLP-1 (glucagon-like peptide-1), which has three main effects: Slows food movement through your stomach, helping you feel fuller for longer Communicates with your brains appetite centre (the hypothalamus) to reduce hunger Improves blood sugar control by enhancing insulin function The natural GLP-1 hormone lasts only minutes before being cleared
Do not take before bedtime
There may be differing opinions or unique experiences
Doses are titrated based on patient tolerance and provider protocol
